Mesothelioma is a rare and aggressive cancer that creates multiple challenges for patients and caregivers. Immune checkpoint inhibitors have recently shown promise to bring hope to people suffering from this devastating cancer. New data from Australia, however, is questioning their effectiveness and safety. Patients and caregivers must understand immunotherapy and[…]
Latest Immunotherapy Treatments
Immunotherapy Might Not Be a Good Option for Mesothelioma
Mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure that creates challenges for patients and caregivers. Immune checkpoint inhibitors have brought hope to patients, but new data from Australia is raising questions about their safety and effectiveness. In order to make informed decisions, patients must understand all[…]
PORT-7 for the Treatment of Mesothelioma
Results from a clinical trial being performed on malignant pleural mesothelioma patients will be presented at the American Association for Cancer Research meeting being held in Chicago, Illinois. Results will be posted by internationally known mesothelioma expert Dr. Luciano Mutti of the department of Applied Clinical Sciences and Biotechnology at[…]
Immunotherapy to Treat Pleural Mesothelioma
Malignant pleural mesothelioma is a rare and very aggressive cancer with a poor outlook. One cancer treatment has brought hope though. The treatment is known as immune checkpoint inhibitors. There is potential for better outcomes when patients are given this treatment. A new article in Open Respiratory Archives provides a[…]
CAR-T Cell Therapy for Mesothelioma
Mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure. With the disease being rare, there are limited treatment options for the disease. This is especially true for elderly patients. They can struggle with conventional therapies due to their age and health problems. One therapy known as Chimeric[…]
Drug Factories to Treat Mesothelioma
Researchers from Rice University and Baylor College of Medicine developed a new treatment that can eliminate advanced stage mesothelioma tumors in mice within days. The breakthrough treatment used Rice’s cytokine drug factory implants with a checkpoint inhibitor drug. This combination is showing great potential in mesothelioma preclinical trials. The treatment[…]
Ipilimumab and Nivolumab for the Treatment of Mesothelioma
Mesothelioma is a difficult diagnosis to receive. With this diagnosis comes treatment regimens and their effects on the body. The United Kingdom has a new set of standard treatments for mesothelioma which include Ipilimumab and Nivolumab. A new article in the journal Lung Cancer reviews Ipilimumab and Nivolumab results, using[…]
Keytruda and Chemotherapy Improve Survival in Mesothelioma Patients
The U.S Food and Drug Administration has accepted a priority review for a new Supplemental Biologics License Application. This could be a new era in the management of pleural mesothelioma, leading to a better future for those diagnosed with the cancer. The review is looking for approval of Keytruda used[…]
Immune Checkpoint Inhibitors Can Improve Survival in Mesothelioma Patients
Malignant pleural mesothelioma is a rare cancer that is hard to treat. There is a poor prognosis for people diagnosed with mesothelioma, but there is hope in the form of immune checkpoint inhibitors. There could be a chance of better outcomes in mesothelioma patients. A new article in Open Respiratory[…]
Galinpepimut-S Alongside Opdivo Improves Survival in Mesothelioma Patients
Sellas Life Sciences recently reported results from its Phase I clinical trial showing that survival was improved in pleural mesothelioma patients due to its treatment. The trial looked at the treatment called galinpepimut-S (GPS), an immunotherapy vaccine. There were 10 patients in the study with relapsed or refractory mesothelioma. Nine[…]
